Clinical Trials

Strategies for engaging, managing KOLs in the pharma industry

April 8, 2024 - Key opinion leaders (KOLs) are healthcare providers (HCPs) and industry leaders who play a critical role in the healthcare industry, acting as vital stakeholders for the sector, including life sciences and pharmaceutical companies. Appropriate KOL engagement and management by pharmaceutical companies can help bolster the company’s reputation, guide research and business...

Read More


More Articles

Drawbridge Health’s NanoDrop gains FDA clearance for at-home blood sampling

by Alivia Kaylor

Drawbridge Health, a pioneering healthcare technology company, announced an innovative achievement today as its advanced at-home blood sampling device, NanoDrop Lancet, received United States Food and...

Comparing inflammatory bowel disease treatment options

by Veronica Salib

Last month, AbbVie sponsored several presentations and posters at the European Crohn's and Colitis Organization’s (ECCO) annual congress. Among these abstracts was the SEQUENCE study, which compared risankizumab and ustekinumab...

AstraZeneca acquires Fusion Pharmaceuticals in $2 billion deal

by Veronica Salib

On March 19, 2024, AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals in a $2 billion deal. Through this deal, AstraZeneca will expand its portfolio and gain access to...

FDA ODAC favors 2 CAR T-cell therapies for multiple myeloma

by Veronica Salib

A meeting of the United States FDA Oncologic Drugs Advisory Committee (ODAC) voted to expand the approval of Abecma and Carvykti, two types of chimeric antigen receptor (CAR) T-cell therapies, for...

FDA expands Wegovy indications, adding cardiovascular disease

by Veronica Salib

On March 8, 2024, the United States FDA expanded approval of Wegovy (semaglutide), making it the first weight loss drug that is FDA-approved for obese and overweight patients at high risk for heart...

Semaglutide Minimizes MASLD Severity in Patients with HIV

by Veronica Salib

On Tuesday, March 5, 2024, the NIH issued a release linking semaglutide use with a decreased severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in HIV-positive patients,...

FDA Approves New First-Line Treatment for Pancreatic Adenocarcinoma

by Veronica Salib

Adding to existing pancreatic cancer treatment options, the United States FDA granted Ipsen Biopharmaceuticals approval for Onivyde — generically known as irinotecan liposome — for treating...

Gilead Announced Plans to Acquire CymaBay in a $4.3 Billion Deal

by Veronica Salib

On Monday, February 12, 2024, Gilead Sciences, a major pharmaceutical manufacturer, announced its plans to acquire CymaBay Therapeutics, a clinical-stage biopharmaceutical company with a strong liver...

What Is the Role of the Accelerating Medicines Partnership?

by Veronica Salib

Last week, the Foundation for the National Institutes of Health (FNIH) held its inaugural Accelerating Medicines Partnership (AMP) Program Symposium, discussing the progress of multiple AMP projects. Julie Gerberding, MD, MPH, President...

GLP-1 Receptor Agonists Reduce 24-Hour Ambulatory Blood Pressure

by Veronica Salib

On Monday, February 5, 2024, a research letter published in Hypertension highlighted the benefit of tirzepatide in managing high blood pressure using data from the SURMOUNT study. The letter notes a...

Vertex Non-Opioid Drug Is an Effective Pain Management Medication

by Veronica Salib

On Tuesday, January 30, 2024, Vertex Pharmaceuticals issued a press release announcing that VX-548, its non-opioid pain management drug, effectively reduced pain compared to the placebo across multiple...

NIH-Developed Antibodies Neutralize HIV in Animal Studies

by Veronica Salib

On January 17, 2024, the National Institutes of Health (NIH) issued a media advisory announcing the results of a proof-of-concept identifying three antibodies that protect against various human...

Semaglutide Reduces Weight in Patients with Failed Bariatric Surgery

by Veronica Salib

According to a study published in Obesity, semaglutide effectively triggers weight loss in severely obese patients, including those who have had bariatric surgery to manage weight but have not yielded...

Researcher Study Non-Opioid Pain Medication for Diabetic Neuropathy

by Veronica Salib

On the tail of their win as the first FDA-approved CRISPR-based gene editing therapy, Vertex Pharmaceuticals announced the results of a phase 2 clinical trial for VX-548, a non-opioid pain management...

FDA Launches New Advisory Committee for Genetic Metabolic Diseases

by Veronica Salib

Adding to the lengthy list of advisory committees under its belt, the United States Food and Drug Administration (FDA) announced its plans to create a new advisory committee to specialize in genetic...

Exploring Data Analytics in Pharmaceutical Marketing

by Veronica Salib

As the global understanding of data analytics advances and new techniques come to fruition, nearly every industry is assessing how they can leverage analytics to improve outcomes for their stakeholders. The pharmaceutical industry is...

FDA Approves First Therapy for Progressing Desmoid Tumors

by Veronica Salib

On Monday, November 27, 2023, the United States Food and Drug Administration (FDA) approved Ogsiveo (nirogacestat), making it the first FDA-approved treatment for desmoid tumors. The drug is intended...

Ensuring Equal Clinical Trial Access Across Vulnerable Communities

by Editorial Staff

Clinical trials play a critical role in ensuring the widespread safety of medical products for patients by analyzing product efficacy, safety, and indications. Since clinical trial data is used to guide drug approvals and standards of care...

FDA Approves Truqap, Faslodex for HR-Positive Breast Cancer

by Veronica Salib

On November 16, 2023, the United States Food and Drug Administration approved AstraZeneca’s Truqap (capivasertib) to be administered in combination with fulvestrant for adults with hormone...

Recent Articles